GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Beneish M-Score
中文

IRIDEX (IRIDEX) Beneish M-Score : -2.99 (As of Apr. 24, 2024)


View and export this data going back to 1996. Start your Free Trial

What is IRIDEX Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for IRIDEX's Beneish M-Score or its related term are showing as below:

IRIX' s Beneish M-Score Range Over the Past 10 Years
Min: -3.85   Med: -2.83   Max: 0.43
Current: -2.99

During the past 13 years, the highest Beneish M-Score of IRIDEX was 0.43. The lowest was -3.85. And the median was -2.83.


IRIDEX Beneish M-Score Historical Data

The historical data trend for IRIDEX's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Beneish M-Score Chart

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.49 -3.25 -2.93 -2.13 -2.99

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.13 -2.15 -2.48 -2.63 -2.99

Competitive Comparison of IRIDEX's Beneish M-Score

For the Medical Devices subindustry, IRIDEX's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRIDEX's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where IRIDEX's Beneish M-Score falls into.



IRIDEX Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of IRIDEX for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0856+0.528 * 1.0591+0.404 * 1.118+0.892 * 0.9104+0.115 * 0.9729
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0664+4.679 * -0.09734-0.327 * 1.3715
=-2.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $9.65 Mil.
Revenue was 12.458 + 12.85 + 12.855 + 13.706 = $51.87 Mil.
Gross Profit was 4.885 + 5.621 + 5.363 + 5.938 = $21.81 Mil.
Total Current Assets was $27.45 Mil.
Total Assets was $34.44 Mil.
Property, Plant and Equipment(Net PPE) was $2.98 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.03 Mil.
Selling, General, & Admin. Expense(SGA) was $24.99 Mil.
Total Current Liabilities was $12.97 Mil.
Long-Term Debt & Capital Lease Obligation was $1.75 Mil.
Net Income was -2.96 + -1.754 + -2.766 + -2.09 = $-9.57 Mil.
Non Operating Income was 0.181 + -0.058 + 0.138 + 0.266 = $0.53 Mil.
Cash Flow from Operations was -0.979 + -1.782 + -1.141 + -2.843 = $-6.75 Mil.
Total Receivables was $9.77 Mil.
Revenue was 15.195 + 14.635 + 13.755 + 13.387 = $56.97 Mil.
Gross Profit was 6.664 + 6.46 + 6.267 + 5.977 = $25.37 Mil.
Total Current Assets was $35.77 Mil.
Total Assets was $42.29 Mil.
Property, Plant and Equipment(Net PPE) was $2.13 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.38 Mil.
Selling, General, & Admin. Expense(SGA) was $25.74 Mil.
Total Current Liabilities was $12.45 Mil.
Long-Term Debt & Capital Lease Obligation was $0.73 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9.654 / 51.869) / (9.768 / 56.972)
=0.186123 / 0.171453
=1.0856

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(25.368 / 56.972) / (21.807 / 51.869)
=0.445271 / 0.420425
=1.0591

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (27.45 + 2.983) / 34.436) / (1 - (35.766 + 2.127) / 42.29)
=0.116245 / 0.103973
=1.118

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=51.869 / 56.972
=0.9104

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.384 / (1.384 + 2.127)) / (2.032 / (2.032 + 2.983))
=0.39419 / 0.405184
=0.9729

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(24.985 / 51.869) / (25.735 / 56.972)
=0.481694 / 0.451713
=1.0664

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.751 + 12.974) / 34.436) / ((0.732 + 12.453) / 42.29)
=0.427605 / 0.311776
=1.3715

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-9.57 - 0.527 - -6.745) / 34.436
=-0.09734

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

IRIDEX has a M-score of -2.99 suggests that the company is unlikely to be a manipulator.


IRIDEX (IRIDEX) Business Description

Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines

From GuruFocus

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022

By GuruFocusNews GuruFocusNews 04-28-2022

Iridex to Report First Quarter Financial Results on May 11, 2023

By sperokesalga sperokesalga 04-27-2023

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-11-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-22-2022

Iridex to Present at the 34th Annual Roth Conference

By GuruFocusNews GuruFocusNews 03-08-2022